Home › Breast Cancer › NCT04824027
Breast Elasticity Imaging During Neoadjuvant Chemotherapy
Predicting Response to Neoadjuvant Chemotherapy Using Harmonic Motion Imaging in Women With Breast Cancer
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: * Women age ≥18 * Deemed eligible to receive neoadjuvant systemic therapy as per the treating physician, with the dose and schedule deemed appropriate by the treating physician. * Any stage invasive breast cancer provided the primary breast tumor size is ≥ 4 mm Exclusion criteria: * Patient is pregnant or lactating * Presence of breast implants * History of laser or radiation therapy to the affected breast
About the study
For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.
What is being tested
- Harmonic motion imaging (procedure)
Sponsor: Columbia University · Participants: 50 · Started: Jun 14, 2021
Contact the study team
- Elisa Konofagou, PhD · Phone: 212-342-1612
- Yangpei Liu, MSc · Phone: 212-342-1612
Official record on ClinicalTrials.gov — NCT04824027
Locations in the U.S.
| New York | Columbia University Irving Medical Center/NYP, New York |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.